Home › Compare › BJINF vs ABBV
BJINF yields 5.21% · ABBV yields 3.06%● Live data
📍 BJINF pulled ahead of the other in Year 3
Combined, BJINF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BJINF + ABBV for your $10,000?
Beijing Enterprises Holdings Limited, an investment holding company, engages in piped gas, brewery, water and environmental, solid waste treatment, and other businesses in Mainland China and Germany. Its Piped Gas Operation segment distributes and sells piped natural gas and gas-related equipment; provides natural gas transmission services, as well as repair and maintenance services; surveys and plots underground construction projects; and installs gas pipelines and related equipment. The company's Brewery Operation segment produces, distributes, and sells brewery products. Its Water and Environmental segment constructs sewage and water treatment plants and other infrastructural facilities; provides construction services for renovation projects; offers sewage treatment, and water treatment and distribution services, as well as consultancy services; and licenses technical know-how related to sewage treatment. The company's Solid Waste Treatment segment is involved in the construction and operation of waste incineration plants; waste treatment; sale of electricity; generation of heat and stream from waste incineration. Its Corporate and Others segment offers consultation and property investment services. The company also engages in the production and sale of beer; and issue of guaranteed bonds and notes. Beijing Enterprises Holdings Limited was founded in 1997 and is based in Wan Chai, Hong Kong. Beijing Enterprises Holdings Limited is a subsidiary of Beijing Enterprises Group (BVI) Company Limited.
Full BJINF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.